Corresponding Author: Brian H. Buck, MD, MSc, Division of Neurology, Department of Medicine, University of Alberta, 7-112H Clinical Sciences Bldg, 11350-83 Ave NW, Edmonton, AB T6G2G3, Canada (email@example.com).
Accepted for Publication: April 4, 2021.
Author Contributions: Drs Buck and Hill had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Buck, Hill, Quinn, Butcher, Menon, Gulamhusein, Barber, Demchuk, Shuaib, Exner.
Acquisition, analysis, or interpretation of data: Buck, Hill, Quinn, Butcher, Menon, Siddiqui, Coutts, Jeerakathil, Smith, Khan, Barber, Jickling, Reyes, Save, Fairall, Piquette, Kamal, Chew, Demchuk, Shuaib.
Drafting of the manuscript: Buck, Khan, Barber, Reyes, Exner.
Critical revision of the manuscript for important intellectual content: Buck, Hill, Quinn, Butcher, Menon, Gulamhusein, Siddiqui, Coutts, Jeerakathil, Smith, Khan, Barber, Jickling, Save, Fairall, Piquette, Kamal, Chew, Demchuk, Shuaib, Exner.
Statistical analysis: Buck, Hill, Menon.
Obtained funding: Buck, Hill, Demchuk, Exner.
Administrative, technical, or material support: Buck, Hill, Menon, Gulamhusein, Jeerakathil, Khan, Reyes, Save, Fairall, Piquette, Kamal, Demchuk, Shuaib, Exner.
Supervision: Buck, Hill, Gulamhusein, Exner.
Conflict of Interest Disclosures: Dr Buck reported receiving research funding from Alberta Innovates Health Solutions. Dr Hill reported receiving grants from NoNO Inc, Boehringer Ingelheim Canada, Medtronic LLC; receiving personal fees from Sun Pharma; being involved in a US patent licensed to Circle Neurovascular Inc; and serving as director for Circle Neurovascular Inc, the Canadian Stroke Consortium, and the Canadian Neuroscience Federation. Dr Quinn reported receiving personal fees from Bristol-Myers Squibb/Pfizer; and receiving grants from Bayer. Dr Butcher reported receiving personal fees from Medtronic, Boehringer-Ingelheim, Servier, Bayer, and Bristol-Myers Squibb/Pfizer; and receiving grants or other research funding from Boehringer-Ingelheim, Bayer, Pfizer, Servier Canada, and Bristol-Myers Squibb/Pfizer. Dr Menon reported holding shares in Circle NVI. Dr Smith reported receiving consulting fees from Alnylam, Biogen, Bayer, and Javelin; and receiving royalties from UpToDate. Dr Jickling reported receiving grants from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. Dr Kamal reported receiving personal fees for serving as part owner of DESTINE Health Inc; and receiving grants from the Canadian Institutes of Health Research. Dr Demchuk reported receiving personal fees from Bristol-Myers Squibb/Pfizer. Dr Exner reported being chief medical officer and minority shareholder in HelpWear Inc; receiving consulting fees and research funding from Abbott Medical, Boston Scientific, GE Healthcare, and Medtronic Inc; and receiving nonfinancial support and having stock options in Analytics for Life. No other disclosures were reported.
Funding/Suppport: This study was supported by Alberta Innovates Health Solutions Collaborative Research and Innovations Opportunities and by grant 201300474 from the Partnership for Research and Innovation in the Health System, government of Alberta. Unrestricted in-kind support (implantable loop recorder devices and the electrocardiographic core laboratory) was provided by Medtronic Canada.
Role of the Funder/Sponsor: The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 4.
WN , Ovbiagele
B , Black
et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke
. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024PubMedGoogle ScholarCrossref
T , Lindsay
MP , Côté
et al. Canadian stroke best practice recommendations: secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int J Stroke
. 2018;13(4):420-443. doi:10.1177/1747493017743062
R , Gröschel
K , Gelbrich
et al; Find-AF(randomised) Investigators and Coordinators. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED
): an open-label randomised controlled trial. Lancet Neurol
. 2017;16(4):282-290. doi:10.1016/S1474-4422(17)30002-9PubMedGoogle ScholarCrossref
G , Katsanos
AH , Köhrmann
et al. Duration of implantable cardiac monitoring and detection of atrial fibrillation in ischemic stroke patients: a systematic review and meta-analysis. J Stroke
. 2019;21(3):302-311. doi:10.5853/jos.2019.01067PubMedGoogle ScholarCrossref
RA , Di Lazzaro
V , Rymer
et al. Infarct topography and detection of atrial fibrillation in cryptogenic stroke: results from CRYSTAL AF. Cerebrovasc Dis
. 2015;40(1-2):91-96. doi:10.1159/000437018PubMedGoogle ScholarCrossref
J , Fieuws
S , Lansberg
MG , Lemmens
R . Detection of atrial fibrillation among patients with stroke due to large or small vessel disease: a meta-analysis. J Am Heart Assoc
. 2016;5(9):e004151. doi:10.1161/JAHA.116.004151PubMedGoogle Scholar
PA , Taylor
R , Minor
et al; REDCap Consortium. The REDCap Consortium: building an international community of software platform partners. J Biomed Inform
. 2019;95:103208. doi:10.1016/j.jbi.2019.103208PubMedGoogle Scholar
Jr , Bendixen
BH , Kappelle
et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke
. 1993;24(1):35-41. doi:10.1161/01.STR.24.1.35PubMedGoogle ScholarCrossref
S , Kearon
C ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost
. 2005;3(4):692-694. doi:10.1111/j.1538-7836.2005.01204.xPubMedGoogle ScholarCrossref
LA , Cipriano
LE , Saposnik
G , Ruíz Vargas
E , Riccio
PM , Hachinski
V . Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol
. 2015;14(4):377-387. doi:10.1016/S1474-4422(15)70027-XPubMedGoogle ScholarCrossref
DS , Rennert-May
E , Spackman
E , Mark
DB , Exner
DV . Cost-effectiveness of extended electrocardiogram monitoring for atrial fibrillation after stroke: a systematic review. Stroke
. 2020;51:2244-2248. PubMedGoogle ScholarCrossref
H , Longstreth
Jr , Tirschwell
et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke
. 2019;14(2):207-214. doi:10.1177/1747493018799981PubMedGoogle ScholarCrossref
RD , Alings
M , Connolly
et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J
. 2017;189:137-145. doi:10.1016/j.ahj.2017.04.008PubMedGoogle ScholarCrossref